7/7/2019 Obscene Insider Selling of Galectin Therapeutics (GALT): Lost Confidence? – Street


thestreetsweeper.org/obscene-insider-selling-of-galectin-therapeutics-galt-lost-confidence/ 1/12


Home  Blog 2  Uncategorized  Obscene Insider Selling of Galectin Therapeu


OBSCENE INSIDER SE
GALECTIN THERAPEUTICS


CONFIDENCE


Galectin Therapeutics (GALT) insiders are selling obscene amounts of stock, undoubtedly laugh
investors scoop up shares unloaded by insiders who bought shares for pocket change and in s


The chief seller is the chief executive …


*CEO’s Out, Other Insiders Can’t Sell Fast Enough


/  0/  Sonya Colberg


OBSCENE INSIDER SELLING OF GALECTIN THERAPEUTICS (GALT): LOST CONFIDE


15
JUN  





Public Oath Clean Up Crew Legal Disclaimer
TURTLE BEACH (HEAR): TOO EXPENSIVE! GENPREX (GNPX): ANOTHER INTROGEN BOMB?



http://thestreetsweeper.org/

http://thestreetsweeper.org/blog-2/

http://thestreetsweeper.org/category/uncategorized/

http://thestreetsweeper.org/obscene-insider-selling-of-galectin-therapeutics-galt-lost-confidence/

https://finance.yahoo.com/quote/GALT/

http://thestreetsweeper.org/author/anshul/

http://thestreetsweeper.org/obscene-insider-selling-of-galectin-therapeutics-galt-lost-confidence/

http://thestreetsweeper.org/

http://thestreetsweeper.org/public-oath/

http://thestreetsweeper.org/clean-up-crew/

http://thestreetsweeper.org/legal-disclaimer/

http://thestreetsweeper.org/investment-tools/

http://thestreetsweeper.org/turtle-beach-hear-too-expensive/

http://thestreetsweeper.org/genprex-gnpx-another-introgen-bomb/
7/7/2019 Obscene Insider Selling of Galectin Therapeutics (GALT): Lost Confidence? – Street


thestreetsweeper.org/obscene-insider-selling-of-galectin-therapeutics-galt-lost-confidence/ 2/12


Two days after being named the new CEO and three weeks before officially taking the position
stock.


He exercised options at $0 and sold his last share on Wednesday of this week:


(Source: Company SEC filings)


As a member of the roundly criticized management team, the new CEO acquired shares over t
officer.


On June 8 and June 11, Mr. Shlevin tanked up on cheap options, most at under $1, and sold nearly





Public Oath Clean Up Crew Legal Disclaimer



https://globenewswire.com/news-release/2018/06/12/1520343/0/en/Galectin-Therapeutics-Inc-Announces-New-CEO.html

https://www.sec.gov/Archives/edgar/data/1133416/000117902218000051/xslF345X03/edgar.xml

http://thestreetsweeper.org/

http://thestreetsweeper.org/public-oath/

http://thestreetsweeper.org/clean-up-crew/

http://thestreetsweeper.org/legal-disclaimer/

http://thestreetsweeper.org/investment-tools/
7/7/2019 Obscene Insider Selling of Galectin Therapeutics (GALT): Lost Confidence? – Street


thestreetsweeper.org/obscene-insider-selling-of-galectin-therapeutics-galt-lost-confidence/ 3/12


(Source: Company SEC filings)


In the last two weeks, Mr. Shlevin has pocketed around $2 million dumping more than 350,000 s


This week, another big seller was Chief Financial Officer Jack Callicutt, who exercised options a
He’s left with only 1,260 shares.





Public Oath Clean Up Crew Legal Disclaimer



https://www.nasdaq.com/quotes/insiders/shlevin-harold-h-888628

http://thestreetsweeper.org/

http://thestreetsweeper.org/public-oath/

http://thestreetsweeper.org/clean-up-crew/

http://thestreetsweeper.org/legal-disclaimer/

http://thestreetsweeper.org/investment-tools/
7/7/2019 Obscene Insider Selling of Galectin Therapeutics (GALT): Lost Confidence? – Street


thestreetsweeper.org/obscene-insider-selling-of-galectin-therapeutics-galt-lost-confidence/ 4/12


(Source: Company SEC filing)


Mr. Callicutt last week unloaded 120,000 shares after exercising cheap $0.87 and $1.37 options.


(Source: Company SEC filing)


Not surprisingly lame duck CEO, Dr. Peter Traber, has been selling shares, too.





Public Oath Clean Up Crew Legal Disclaimer



https://www.sec.gov/Archives/edgar/data/1133416/000117902218000048/xslF345X03/edgar.xml

http://thestreetsweeper.org/

http://thestreetsweeper.org/public-oath/

http://thestreetsweeper.org/clean-up-crew/

http://thestreetsweeper.org/legal-disclaimer/

http://thestreetsweeper.org/investment-tools/
7/7/2019 Obscene Insider Selling of Galectin Therapeutics (GALT): Lost Confidence? – Street


thestreetsweeper.org/obscene-insider-selling-of-galectin-therapeutics-galt-lost-confidence/ 5/12


dumping shares, too.


On Thursday, June 14, Galectin co-founder and director James Czirr, as managing member of 1
thousand shares from the fund.


und.





Public Oath Clean Up Crew Legal Disclaimer



http://investor.galectintherapeutics.com/board-directors/james-czirr

http://thestreetsweeper.org/

http://thestreetsweeper.org/public-oath/

http://thestreetsweeper.org/clean-up-crew/

http://thestreetsweeper.org/legal-disclaimer/

http://thestreetsweeper.org/investment-tools/
7/7/2019 Obscene Insider Selling of Galectin Therapeutics (GALT): Lost Confidence? – Street


thestreetsweeper.org/obscene-insider-selling-of-galectin-therapeutics-galt-lost-confidence/ 6/12


(Source: Company SEC filing)


Last Friday, records show 10X Fund also sold off 110,000 shares … for about 2 bucks cheaper than


(Source: Company SEC filing)


In the last three months, insiders have bought NO shares and sold almost 1 million shares:





Public Oath Clean Up Crew Legal Disclaimer



http://thestreetsweeper.org/

http://thestreetsweeper.org/public-oath/

http://thestreetsweeper.org/clean-up-crew/

http://thestreetsweeper.org/legal-disclaimer/

http://thestreetsweeper.org/investment-tools/
7/7/2019 Obscene Insider Selling of Galectin Therapeutics (GALT): Lost Confidence? – Street


thestreetsweeper.org/obscene-insider-selling-of-galectin-therapeutics-galt-lost-confidence/ 7/12


(Source: Nasdaq)


Would insiders be dumping their stock it they really believed in Galectin as it struggles to advan
steatohepatitis, a primary cause of liver cancer?


No way … and there are even more problems.


*Running On Fumes, Dilution Looms


Meanwhile, cash is burning up at a rate of $3.5 million per quarter.


With less than $4 million at the end of March, the company would have been down to fumes by


The company has no way of making money for years to come … if ever.


Sure, there’s a $10 million line of credit which could get Galectin by until early next year … if they 


*Big Losses, Big Failures


But, despite two failures to meet primary endpoints (page 17), the company plans to move forw


They hope to go into Phase III trials. But this more demanding phase is typically a 2-year to 5-ye
participants. Average costs of Phase III clinical trials range from $11.5 million to $52.9 million… mo


Ever since inception 18 years ago, Galectin has handed shareholders loss after loss, year after y
in sight.


“If we are unsuccessful in raising additional capital to fund operations before March 31, 2019, w
company states.


*Massive Rivals


This is a highly competitive field in which a couple of competitors have recently shown notable


Galmed Pharmaceuticals (GLMD) has released data indicating its NASH candidate, Aramchol, s
enzymes used to diagnose liver damage. Also, patients receiving 400 mg per day showed a ba
content, while a statistically significant 47% of patients who received 600 mg showed a 5% or gr
company plans to meet with the FDA later this year to consider design of a larger, pivotal trial.


Galmed reported $1 million revenue in 2017 and $13 million cash.


Meanwhile, Madrigal Pharmaceuticals (MDGL) plans to meet with the FDA soon to discuss an up
MGL-3196 cut liver fat content 36.3% from baseline, versus 9.6% reduction for placebo. At 36 wee
symptoms, versus only 6% of the placebo group.


The company is working with an investment bank regarding a potential sale, Bloomberg report



Public Oath Clean Up Crew Legal Disclaimer



https://www.nasdaq.com/symbol/galt/insider-trades

https://www.sec.gov/Archives/edgar/data/1133416/000119312518100592/d498563d10k.htm

https://www.accordclinical.com/clinical-study/types-of-clinical-trials/phase-iii-clinical-trials/

https://www.centerpointclinicalservices.com/blog-posts/driving-drive-drug-innovation-and-market-access-part-1-clinical-trial-cost-breakdown/

https://finance.yahoo.com/quote/GLMD/balance-sheet?p=GLMD

https://finance.yahoo.com/news/3-nash-stocks-could-soar-120700056.html

https://finance.yahoo.com/quote/MDGL/balance-sheet?p=MDGL

http://thestreetsweeper.org/

http://thestreetsweeper.org/public-oath/

http://thestreetsweeper.org/clean-up-crew/

http://thestreetsweeper.org/legal-disclaimer/

http://thestreetsweeper.org/investment-tools/
7/7/2019 Obscene Insider Selling of Galectin Therapeutics (GALT): Lost Confidence? – Street


thestreetsweeper.org/obscene-insider-selling-of-galectin-therapeutics-galt-lost-confidence/ 8/12


Madrigal reported $38 million in cash as of March 31.


Some of the biggest names in pharma are among those promoting more than 50 drugs consid
of development (the list contains some misspellings as it has been compiled by a non-native E





Public Oath Clean Up Crew Legal Disclaimer



http://thestreetsweeper.org/

http://thestreetsweeper.org/public-oath/

http://thestreetsweeper.org/clean-up-crew/

http://thestreetsweeper.org/legal-disclaimer/

http://thestreetsweeper.org/investment-tools/
7/7/2019 Obscene Insider Selling of Galectin Therapeutics (GALT): Lost Confidence? – Street


thestreetsweeper.org/obscene-insider-selling-of-galectin-therapeutics-galt-lost-confidence/ 9/12





Public Oath Clean Up Crew Legal Disclaimer



http://thestreetsweeper.org/

http://thestreetsweeper.org/public-oath/

http://thestreetsweeper.org/clean-up-crew/

http://thestreetsweeper.org/legal-disclaimer/

http://thestreetsweeper.org/investment-tools/
7/7/2019 Obscene Insider Selling of Galectin Therapeutics (GALT): Lost Confidence? – Street


thestreetsweeper.org/obscene-insider-selling-of-galectin-therapeutics-galt-lost-confidence/ 10/12


About Author


SONYA COLBERG


RELATED POSTS


*Conclusion


Looming ahead, investors will likely see more insider selling, substantial dilution and great disap


We expect this stock will plunge near-term to $5 per share.


* Important Disclosure: The owners of TheStreetSweeper hold a short position in GALT and standshort


* Editor’s Note: As a matter of policy, TheStreetSweeper prohibits members of its editorial team 
that they cover. To contact Sonya Colberg, the author of this story, please send an email to stre


 Uncategorized





Public Oath Clean Up Crew Legal Disclaimer



http://thestreetsweeper.org/author/anshul/

http://thestreetsweeper.org/category/uncategorized/

http://thestreetsweeper.org/

http://thestreetsweeper.org/public-oath/

http://thestreetsweeper.org/clean-up-crew/

http://thestreetsweeper.org/legal-disclaimer/

http://thestreetsweeper.org/investment-tools/
7/7/2019 Obscene Insider Selling of Galectin Therapeutics (GALT): Lost Confidence? – Street


thestreetsweeper.org/obscene-insider-selling-of-galectin-therapeutics-galt-lost-confidence/ 11/12


Reviewer’s snubs, declining market
share and dicey technicals may soon
kick sand in Turtle Beach’s face. We
believe Turtle Beach (HEAR) has basked
long enough in its 150% run-up over
three days and is now changing
course. Exceeding Price Target On May
9, the gaming headset
company reported improved revenue
of $40.88 million,...


